Amid rapid technological advancements and regulatory uncertainty, navigating the life sciences ecosystem can be challenging. In the video above, Chelsea Anderson, Rob Freedman, and Amanda L. Rose share what life sciences investors are looking for when choosing where to place their support.
Watch them discuss investor appetite for good data and a strong operational plan for completing phase 3 clinical trials; the continued interest in the oncology space and an increase in medical device and diagnostic companies going public; the evolving world of AI in drug discovery; and the effects of FDA uncertainty on IPO investment.